Table 3 Primary and secondary safety endpoints
Safety endpoints | VARTD (n = 21) |
|---|---|
Primary composite endpoint, n (%) | 6 (29) |
Primary endpoint components, n (%) | |
Death | 2 (10) |
New-onset organ failure | 1 (5) |
Enterocutaneous fistula†| 4 (19) |
Pancreatic fistula†| 0 |
Other fistulae‡ | 1 (5) |
Intra-abdominal bleeding†| 2 (10) |
Visceral perforation†| 0 |
Secondary endpoints | |
Endocrine and exocrine function, n (%) | |
 New-onset diabetes | 3 (14) |
 New diagnosis of pancreatic insufficiency | 3 (14) |
 Postoperative ICU admission, n (%) | 5 (24) |
Length of postoperative ICU stay, days | |
 Mean (SD) | 2.6 (1.7) |
 Median (IQR) | 3.0 (1.0‒4.0) |
 Range | 1.0‒5.0 |
Biliary strictures, n (%) | 2 (10) |
Incisional hernia, n (%) | 0 |
Wound infections, n (%) | 21 (100) |
Length of hospital stay after VARTD, days | |
 Mean (SD) | 51.8 (33.1) |
 Median (IQR) | 40.0 (31.0‒63.0) |
 Range | 24.0‒139.0 |
Length of stay at our tertiary center, days | |
 Mean (SD) | 74.7 (41.2) |
 Median (IQR) | 68.0 (41.0‒89.5) |
 Range | 32.0‒175.0 |
Length of stay after the onset of pancreatitis, days | |
 Mean (SD) | 114.9 (42.1) |
 Median (IQR) | 115.0 (81.0‒135.5) |
 Range | 63.0‒236.0 |